CMND adds Israeli site to Alcohol Use Disorder trial – Form 6-K

Clearmind Medicine Inc. (CMND) has filed a Form 6-K for June 2025.

Rhea-AI Filing Summary

Clearmind Medicine Inc. (CMND) has filed a Form 6-K for June 2025.

The filing mainly furnishes a press release dated 23 June 2025 entitled “Clearmind Medicine Adds Leading Israeli Clinical Site to Its Ongoing Clinical Trial for Alcohol Use Disorder.” No financial statements, earnings data, or transactional details accompany the report. The company simply notifies investors that the first two paragraphs of the press release are incorporated by reference into several existing U.S. registration statements on Forms F-3 (File Nos. 333-275991, 333-270859, 333-273293) and S-8 (File No. 333-283695).

The filing is signed by CEO Adi Zuloff-Shani on 23 June 2025. Aside from the clinical-site expansion disclosure, there are no other material events, financial metrics, or risk factors discussed.

Positive

• Expanded clinical infrastructure: the company added a respected Israeli site to its ongoing Alcohol Use Disorder trial, potentially supporting faster enrollment and broader data.

Negative

• None.

Insights

Biotech Research Analyst

TL;DR — Site addition modestly improves trial execution; no hard data disclosed.

Adding a prominent Israeli site could accelerate patient enrollment and strengthen data credibility in Clearmind’s alcohol-use-disorder study, but the 6-K lacks enrollment targets, timelines, or regulatory guidance. Because no efficacy or financial metrics are supplied, the update is operational rather than transformational. Material impact is limited until further clinical milestones or topline results emerge.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Clearmind Medicine (CMND) disclose in its June 2025 Form 6-K?

The filing furnishes a press release announcing the addition of a leading Israeli clinical site to the company’s ongoing Alcohol Use Disorder trial.

When was the related press release issued?

23 June 2025.

Which registration statements incorporate the press-release paragraphs by reference?

Forms F-3 (File Nos. 333-275991, 333-270859, 333-273293) and Form S-8 (File No. 333-283695).

Who signed the Form 6-K for Clearmind Medicine?

Adi Zuloff-Shani, Chief Executive Officer, signed on 23 June 2025.

Does the Form 6-K include any financial results or earnings data?

No. The filing solely relates to an operational update on the clinical trial site expansion.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/23/2025 - 07:56 AM Learn about SEC filing dates

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

 

For the month of: June 2025

 

Commission file number: 001-41557

 

CLEARMIND MEDICINE INC.

(Translation of registrant’s name into English)

 

101 – 1220 West 6th Avenue

Vancouver, British Columbia

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒    Form 40-F ☐

 

 

 

 

 

CONTENTS

 

Attached hereto and incorporated herein is the Registrant’s press release issued on June 23, 2025, titled “Clearmind Medicine Adds Leading Israeli Clinical Site to Its Ongoing Clinical Trial for Alcohol Use Disorder”.

 

The first and second paragraphs of the press release attached to this Form 6-K as Exhibit 99.1 are incorporated by reference into the Registrant’s Registration Statements on Form F-3 (File Nos. 333-275991, 333-270859, 333-273293) and Form S-8 (File No. 333-283695), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

 

1

 

 

EXHIBIT INDEX

 

Exhibit No.	 	 
99.1	 	Press release titled: “Clearmind Medicine Adds Leading Israeli Clinical Site to Its Ongoing Clinical Trial for Alcohol Use Disorder”

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 	Clearmind Medicine, Inc.
 	(Registrant)
 	 	 
Date: June 23, 2025	By:	/s/ Adi Zuloff-Shani
 	Name: 	Adi Zuloff-Shani
 	Title:	Chief Executive Officer

 

3